Vident Investment Advisory’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Vident Investment Advisory’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-61,062	Closed	-$2.24M	–	953
2018 Q3	$2.24M	Sell	61,062 -4,070	-6%	-$131K	0.09%	299
2018 Q2	$2.28M	Buy	65,132 +22,803	+54%	+$874K	0.09%	303
2018 Q1	$1.7M	Buy	42,329 +11,501	+37%	+$421K	0.07%	332
2017 Q4	$1.16M	Buy	30,828 +8,865	+40%	+$387K	0.05%	362
2017 Q3	$1.17M	Buy	21,963 +552	+3%	+$32.8K	0.06%	346
2017 Q2	$1.22M	Buy	21,411 +5,602	+35%	+$281K	0.1%	300
2017 Q1	$850K	Buy	15,809 +2,634	+20%	+$149K	0.08%	319
2016 Q4	$751K	Buy	13,175 +1,577	+14%	+$95.4K	0.09%	304
2016 Q3	$721K	Sell	11,598 -462	-4%	-$32.7K	0.1%	311
2016 Q2	$682K	Buy	12,060 +2,668	+28%	+$162K	0.1%	327
2016 Q1	$602	Buy	9,392 +4,383	+88%	+$355K	0.04%	366
2015 Q4	$705K	Buy	+5,009	New	+$680K	0.09%	347

Other funds holding KDNY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Vident Investment Advisory's KDNY Position: Q4 2018 in Review

Vident Investment Advisory sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2018, closing a stake of 61,062 shares — an estimated $2.24M sold.

Vident Investment Advisory first reported a position in KDNY in Q4 2015 and held it in 12 quarters. The position peaked at $2.28M in Q2 2018. 85 funds tracked by Wall St. Rank hold KDNY as of Q4 2018.

Vident Investment Advisory reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Vident Investment Advisory sold 61,062 Chinook Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $2.24M.
Vident Investment Advisory first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2015 and held it in 12 quarters.
Vident Investment Advisory's Chinook Therapeutics, Inc. Common Stock position peaked at $2.28M in Q2 2018.
85 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Vident Investment Advisory's 13F filing for Q4 2018, filed 14 Feb 2019.